Prognostic value of serial tissue prostate-specific antigen measurements during different hormonal treatments in prostate cancer patients

Clinical Cancer Research

Volumn 6, Issue 5, 2000, Pages 1790-1795

  Grande, Mirtha ^a   Carlström, Kjell ^a   Rozell, Barbro Lundh ^a   Stege, Reinhard ^a   Pousette, Åke ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GONADORELIN AGONIST; GOSERELIN; POLYESTRADIOL PHOSPHATE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ORCHIECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HORMONES; HUMANS; MALE; MICROTOMY; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; ORCHIECTOMY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0034068318     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Killian, C. S., Emrich, L. J., Vargas, F. P., Yang, N., Wang, M. C., Priore, R. L., Murphy, G. P., and Chu, T. M. Relative reliability of five serially measured markers for prognosis of progression in prostate cancer. J. Natl. Cancer Inst., 76: 179-185, 1986.
2. Catalona, W. J., Smith, D. S., Ratliff, T. L., K. M., D., Coplen, D. E., Yuan, J. J. J., Petros, J. A., and Andriole, G. L. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med., 324: 1156-1161, 1991.
3. Chan, D. W., and Sokoll, L. J. Prostate-specific antigen. Update 1997. JIFCC., 9: 1997.
4. Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S., and Redwine, E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med., 317: 909-916, 1987.
5. Hudson, M. A., Bahnson, R. R., and Catalona, W. J. Clinical use of prostate specific antigen in patients with prostate cancer. J. Urol., 142: 1011-1017, 1989.
6. Cooper, E. H., Armitage, T. G., Robinson, M. R., Newling, D. W., Richards, B. R., Smith, P. H., Denis, L., and Sylvester, R. Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer. Cancer (Phila.)., 66: 1025-1028, 1990.
7. Reynard, J. M., Peters, T. J., and Gillatt, D. Prostate-specific antigen and prognosis in patients with metastatic prostate cancer - a multivariable analysis of prostate cancer mortality. Br. J. Urol., 75: 507-515, 1995.
8. Carter, H. B., Partin, A. W., Luderer, A. A., Metter, E. J., Landis, P., Chan, D. W., Fozard, J. L., and Pearson, J. D. Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology, 49: 379-384, 1997.
9. Kawakami, S., Takagi, K., Yonese, J., Ueda, T., Fukui, I., and Kawai, T. Prognostic significance of prostate-specific antigen levels two months after hormonal manipulation of metastatic prostate cancer. Eur. Urol., 32: 58-63, 1997.
10. Hasenson, M., Lundh, B., Stege, R., Carlstrom, K., and Pousette, A. PAP and PSA in prostatic carcinoma cell lines and aspiration biopsies: relation to hormone sensitivity and to cytological grading. Prostate, 14: 83-90, 1989.
11. Stege, R., Lundh, B., Tribukait, B., Pousette, Å., Carlstrom, K., and Haneson, M. Deoxyribonucleic acid ploidy and the direct assay of prostatic acid phosphatase and prostate specific antigen in fine needle aspiration biopsies as diagnostic methods in prostatic carcinoma. J. Urol., 144: 299-302, 1990.
12. Stege, R., Tribukait, B., Lundh, B., Carlstrom, K., Pousette, Å., and Hasenson, M. Quantitative estimation of tissue prostate specific antigen, deoxyribonucleic acid ploidy, and cytological grade in fine needle aspiration biopsies for prognosis of hormonally treated prostatic carcinoma. J. Urol., 148: 833-837, 1992.
13. Stege, R. H., Tribukait, B., Carlstrom, K. A. M., Grande, M., and Pousette, A. H. L. Tissue PSA from fine-needle biopsies of prostatic carcinoma as related to serum PSA, clinical stage, cytological grade, and DNA ploidy. Prostate, 38: 183-188, 1999.
14. Stege, R., Grande, M., Carlstrom, K., Tribukait, B., and Pousette, A. Prognostic significance of tissue prostate-specific antigen in endocrine treated prostate carcinomas. Clin. Cancer Res., 6: 160-165, 2000.
15. Labrie, F., Dupont, A., Bélanger, A., St-Arnaud, R.. Giguére, M., Acourciére, Y., Emond, J., and Monfette, G. Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocrinol. Rev., 7: 67-74, 1986.
16. Carlstrom, K., Stege, R., Henriksson, P., Grande, M., Gunnarsson, P. O., and Pousette, A. Possible bone-preserving capacity of high-dose intramuscular depot estrogen as compared to orchidectomy in the treatment of patients with prostatic carcinoma. Prostate, 31: 193-197, 1997.
17. Hanner, M. The case for TNM (Editorial). Clin. Oncol., 3: 131-135, 1977.
18. Franzén, S., Giertz, G., and Zajicek, J. Cytological diagnosis of prostatic tumours by transrectal aspiration biopsy: a preliminary report. Br. J. Urol., 32: 193-196, 1960.
19. Muller, H., Altenahr, E., Bocking, A., Dhom, G., Faul, P., Gottinger, H., Helpap, B., Hohbach, C., Kastendieck, H., and Leistenscheider, W. Über Klassifikation und Grading des Prostatacarcinoms. Verh. Dtsch. Ges. Pathol., 64: 609-611, 1980.
20. Cox, D. Regression models and life tables. J. Royal Stat. Soc., 34: 187-220, 1972.
21. Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., and Smith, P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br. J. Cancer, 35: 1-39, 1977.
22. Tribukait, B. DNA flow cytometry in carcinoma of the prostate for diagnosis, prognosis and study of tumor biology. Acta Oncol., 30: 187-192, 1991.
23. Yang, Y., Chisholm, G. D., and Habib, F. K. The distribution of PSA, cathepsin-D, and pS2 in BPH and cancer of the prostate. Prostate, 21: 201-208, 1992.
24. Henttu, P., Liao, S. S., and Vihko, P. Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line. Endocrinol., 130: 766-772, 1992.
25. Henttu, P., and Vihko, P. Steroids inversely affect the biosynthesis and secretion of human prostatic acid phosphatase and prostate-specific antigen in the LNCaP cell line. J. Steroid Biochem. Mol. Biol., 41: 349-360, 1992.
26. Carlstrom, K., and Stege, R. Testicular and adrenocortical function in men with prostatic cancer and in healthy age-matched controls. Br. J. Urol., 79: 427-431, 1997.
27. Pousette, A., Carlstrom, K., Tribukait, B., Grande, M., Engstrom, A. H., Henriksson, P., and Stege, R. Prostate-specific antigen in tissue from fine-needle aspiration biopsies. Br. J. Urol., 79 (Suppl 1): 104-106, 1997.